This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

CVS-Aetna remedy is still the right course, DOJ tells court after reviewing public comments

( February 13, 2019, 22:26 GMT | Official Statement) -- MLex Summary: The divestiture of Aetna's standalone Medicare Part D prescription drug business to address concerns in the CVS Health-Aetna deal is still the right choice to address concerns, the US Department of Justice told a court it concluded after reviewing 173 public comments. A federal judge is reviewing the settlement, which the DOJ said it continues to believe "provides an effective and appropriate remedy for the antitrust violations alleged" in its complaint.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login